Walgreens has agreed to a $100 million settlement to resolve claims from consumers and unions that it overcharged insured customers for prescription drugs while allowing members of its Prescription Savings Club to pay significantly less. The settlement, filed in Illinois federal court on Friday, seeks preliminary approval to conclude the case, which involves allegations of fraud, unjust enrichment, and violations of state consumer protection laws.

Details of the Settlement and Consumer Claims

The lawsuit, initially filed in 2017, accuses Walgreens of manipulating prescription drug pricing by failing to report lower prices from its Prescription Savings Club as the "usual and customary" rates when calculating costs for insured customers. Instead, Walgreens allegedly charged insured consumers more than club members, who paid flat-rate, discounted prices for generic medications.

In the court filing, plaintiffs praised the $100 million settlement as "an excellent result for the settlement class," recognizing the challenges and complexities involved in continued litigation. Along with the payout, Walgreens has agreed to close its Prescription Savings Club, which offered discounted rates to uninsured members.

Class Members and Compensation Structure

The proposed class for the settlement includes all individuals who used insurance to pay for Walgreens prescriptions dating back to January 1, 2007. According to the filing, class members will receive compensation based on an estimate of their spending on eligible prescriptions at Walgreens. The class is expected to encompass millions of individuals and thousands of benefit providers, reflecting the extensive reach of Walgreens' pricing practices over the years.

Walgreens To Pay $100M In Suit : Background of the Case and Legal Proceedings

Walgreens previously attempted to dismiss the lawsuit in 2017, but a federal judge largely rejected its motion in 2018. U.S. District Judge John Z. Lee found that the plaintiffs presented sufficient evidence to support claims that Walgreens listed higher "usual and customary" prices for insurance providers, despite offering lower prices to members of its Prescription Savings Club.

Following years of litigation and a motion for class certification in November 2022, settlement discussions began in December 2023 while the certification request was still pending. Walgreens has maintained that it acted within the law, with spokesperson Fraser Engerman noting that the company "admits no wrongdoing" and views the claims as "meritless." Engerman further stated that the savings program was introduced to provide affordable access to medications and that the settlement will allow Walgreens to focus on broader business strategies.

Legal Representation

The plaintiffs, including consumers and union groups, are represented by attorneys Joseph P. Guglielmo, Erin Green Comite, and Amanda Rolon of Scott+Scott Attorneys at Law LLP, along with David W. Mitchell, Arthur L. Shingler III, Paul J. Geller, Mark J. Dearman, and Stuart A. Davidson of Robbins Geller Rudman & Dowd LLP.

As Walgreens moves forward, the settlement represents a notable resolution in the ongoing debate over transparency and fairness in prescription drug pricing for insured and uninsured customers alike.